Celgene, Ionis ink China drug development pacts; Motif touts positive PhIII antibiotic data
A host of biotech startups in China have been making the trek to the US to partner on promising experimental therapies. And we have news of two new pacts this week:
→ Shanghai-based Antengene Corporation inked a collaborative partnership and definitive licensing agreement with Celgene Corporation for its TORC1/TORC2 inhibitor CC- 223 covering China and other Asian nations. Antengene will be fully responsible for the clinical development and commercialization of CC-223 for the defined territories.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.